Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs.2025 The company is based in Waltham, Massachusetts,2014 and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| RGEN | REPLIGEN CORP | 2026-03-03 05:13:36 | 121.67 | -3.3 | -2.64 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RGEN | 0000730272 | REPLIGEN CORP | US7599161095 | 54930006QJ0T5AUO1E71 | 042729386 | Nasdaq | 2836 | Biological Products, (No Diagnostic Substances) | 1231 | DE | 41 SEYON STREET | WALTHAM | MA | 02453 | UNITED STATES | US | 7814499560 | 41 SEYON STREET, WALTHAM, MA, 02453 | 41 SEYON STREET, WALTHAM, MA, 02453 | — | Biotechnology | 1981 | Olivier Loeillot | 1,900 | https://repligen.com | 5,979,282,111 | 56,283,321 | 56,290,749 | Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs.2025 The company is based in Waltham, Massachusetts,2014 and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. | 2026-02-26 16:21:04 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 6,000,000,000 | 20,717,889 | 0.3465 | 56,331,110 | 182,554 | 0.3251 |
| 2024 | 5,979,282,111 | -952,564,917 | -13.7419 | 56,148,556 | 377,481 | 0.6768 |
| 2023 | 6,931,847,028 | -1,979,875,216 | -22.2165 | 55,771,075 | 208,492 | 0.3752 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| James Bylund | Chief Operating Officer | 2024 | 467,181 | 0 | 2,512,360 | 343,904 | 5,000 | 4,170,772 |
| Ralf Kuriyel | Senior Vice President | 2024 | 396,743 | 0 | 1,017,509 | 233,642 | 5,000 | 1,994,138 |
| Olivier Loeillot | President | 2024 | 650,000 | 0 | 4,582,286 | 494,625 | 5,000 | 7,184,359 |
| Jason K. Garland | Chief Financial Officer | 2024 | 550,000 | 0 | 734,225 | 389,400 | 187,592 | 2,107,416 |
| Tony J. Hunt | Chief Executive Officer | 2024 | 733,333 | 0 | 9,310,188 | 652,806 | 5,000 | 20,304,850 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 2,000 |
| 2024 | 1,800 |
| 2023 | 1,800 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 738,256,000 | 634,439,000 | 638,764,000 |
| Cost Of Revenue | 352,011,000 | 359,794,000 | 353,922,000 |
| Gross Profit | — | — | — |
| Research And Development Expenses | 54,177,000 | 43,200,000 | 42,722,000 |
| General And Administrative Expenses | 290,508,000 | 263,368,000 | 218,113,000 |
| Operating Expenses | 683,089,000 | 669,553,000 | 584,188,000 |
| Operating Income | 55,167,000 | -35,114,000 | 54,576,000 |
| Net Income | 48,894,000 | -25,514,000 | 41,577,000 |
| Earnings Per Share Basic | 0.87 | -0.46 | 0.75 |
| Earnings Per Share Diluted | 0.86 | -0.46 | 0.74 |
| Weighted Average Shares Outstanding Basic | 56,234 | 55,937 | 55,720 |
| Weighted Average Shares Outstanding Diluted | 56,561 | 55,937 | 56,377 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 566,021,000 | 757,355,000 | 751,323,000 |
| Marketable Securities Current | 201,607,000 | — | 0 |
| Accounts Receivable | 158,587,000 | 134,115,000 | 124,161,000 |
| Inventories | 170,458,000 | 142,964,000 | 202,321,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 21,567,000 | 12,128,000 | 13,317,000 |
| Total Assets Current | 1,137,385,000 | 1,066,041,000 | 1,111,043,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 186,614,000 | 197,738,000 | 207,440,000 |
| Other Assets Non Current | 4,913,000 | 868,000 | 1,277,000 |
| Total Assets Non Current | 1,812,314,000 | 1,763,625,000 | 1,713,368,000 |
| Total Assets | 2,949,699,000 | 2,829,666,000 | 2,824,411,000 |
| Accounts Payable | 30,010,000 | 32,134,000 | 19,563,000 |
| Deferred Revenue | 14,609,000 | 13,243,000 | 10,287,000 |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 79,208,000 | 62,423,000 | 50,533,000 |
| Total Liabilities Current | 135,826,000 | 126,787,000 | 158,162,000 |
| Long Term Debt | 542,213,000 | 525,567,000 | 510,143,000 |
| Other Liabilities Non Current | 15,555,000 | 16,581,000 | 3,789,000 |
| Total Liabilities Non Current | 707,744,000 | 730,161,000 | 695,046,000 |
| Total Liabilities | 843,570,000 | 856,948,000 | 853,208,000 |
| Common Stock | 563,000 | 561,000 | 558,000 |
| Retained Earnings | 456,248,000 | 407,354,000 | 438,849,000 |
| Accumulated Other Comprehensive Income | -2,531,000 | -52,533,000 | -37,431,000 |
| Total Shareholders Equity | 2,106,129,000 | 1,972,718,000 | 1,971,203,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 78,745,000 | 69,673,000 | 68,085,000 |
| Share Based Compensation Expense | 32,605,000 | 48,070,000 | 25,575,000 |
| Other Non Cash Income Expense | -1,630,000 | 230,000 | -1,231,000 |
| Change In Accounts Receivable | 17,165,000 | 14,031,000 | 3,312,000 |
| Change In Inventories | 14,947,000 | -56,895,000 | -40,973,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | -471,000 | 461,000 |
| Change In Accounts Payable | -4,150,000 | 12,898,000 | -9,803,000 |
| Change In Other Liabilities | 11,813,000 | 6,106,000 | -27,921,000 |
| Cash From Operating Activities | 117,417,000 | 175,394,000 | 113,918,000 |
| Purchases Of Marketable Securities | 200,257,000 | — | — |
| Sales Of Marketable Securities | 0 | 0 | 102,323,000 |
| Acquisition Of Property Plant And Equipment | 23,519,000 | 25,677,000 | 36,222,000 |
| Acquisition Of Business | 70,328,000 | 54,765,000 | 186,642,000 |
| Other Investing Activities | 2,397,000 | -1,287,000 | -32,000 |
| Cash From Investing Activities | -298,474,000 | -86,383,000 | -123,275,000 |
| Tax Withholding For Share Based Compensation | 8,833,000 | 9,882,000 | 13,227,000 |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | — | — | 14,400,000 |
| Repurchase Of Common Stock | 0 | 0 | 14,386,000 |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | 0 | 0 | -45,000 |
| Cash From Financing Activities | -15,205,000 | -82,902,000 | 248,961,000 |
| Change In Cash | -191,334,000 | 6,032,000 | 227,865,000 |
| Cash At End Of Period | 566,021,000 | 757,355,000 | 751,323,000 |
| Income Taxes Paid | 20,925,000 | 19,298,000 | 26,963,000 |
| Interest Paid | — | 6,070,000 | 988,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | 0.87 | -0.46 | 0.75 |
| Price To Earnings Ratio | 188.3448 | -312.913 | 239.7333 |
| Earnings Growth Rate | -289.1304 | -161.3333 | -77.6119 |
| Price Earnings To Growth Ratio | -0.6514 | 1.9395 | -3.0889 |
| Book Value Per Share | 37,452.9466 | 35,266.7823 | 35,376.9383 |
| Price To Book Ratio | 0.0044 | 0.0041 | 0.0051 |
| Ebitda | 171,210,000 | 84,188,000 | 138,576,000 |
| Enterprise Value | -14,593,496.76 | -223,736,428.22 | -231,161,544 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 0.2574 | 0.2664 | 0.2588 |
| Capital Expenditures | 67,621,000 | 59,971,000 | 84,852,000 |
| Free Cash Flow | 49,796,000 | 115,423,000 | 29,066,000 |
| Return On Equity | 0.0232 | -0.0129 | 0.0211 |
| One Year Beta | 1.441 | 1.335 | 1.5771 |
| Three Year Beta | 1.4456 | 1.507 | 1.4452 |
| Five Year Beta | 1.4291 | 1.0621 | 1.0863 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Douglass Brian Robb | CHIEF PRODUCT OFFICER | 2025-12-31 | 2,288 | A | 8,540 |
| Douglass Brian Robb | CHIEF PRODUCT OFFICER | 2025-12-31 | 2,143 | A | 2,143 |
| DAWES KAREN A | Director | 2025-12-17 | 275 | D | 91,821 |
| MUIR GLENN P | Director | 2025-12-16 | 3,366 | A | 36,622 |
| MUIR GLENN P | Director | 2025-12-16 | 3,366 | A | 3,366 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Lisa McClain | 2025-11-21 | MI09 | Sale | 2025-10-31 | Spouse | $1,001 - $15,000 |
| Lisa McClain | 2025-11-21 | MI09 | Sale | 2025-10-30 | Spouse | $1,001 - $15,000 |
| Lisa McClain | 2025-11-21 | MI09 | Purchase | 2025-10-30 | Spouse | $1,001 - $15,000 |
| Lisa McClain | 2025-08-13 | MI09 | Purchase | 2025-07-22 | Spouse | $1,001 - $15,000 |
| Lisa McClain | 2025-08-13 | MI09 | Purchase | 2025-06-11 | Spouse | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| GROUPAMA ASSET MANAGMENT | 2025-12-31 | 1,218,627 | 7,437 | 163.86 |
| Bell Investment Advisors, Inc | 2025-12-31 | 492 | 3 | 164 |
| Pacer Advisors, Inc. | 2025-12-31 | 1,715,450 | 10,469 | 163.86 |
| MV CAPITAL MANAGEMENT, INC. | 2025-12-31 | 328 | 2 | 164 |
| T. Rowe Price Investment Management, Inc. | 2025-12-31 | 105,874,000 | 646,122 | 163.8607 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| RYDEX SERIES FUNDS | 2025-12-31 | Class C | RYDCX | 145 | 23,759.7 | 0.1743 |
| RYDEX SERIES FUNDS | 2025-12-31 | Class A | RYAHX | 145 | 23,759.7 | 0.1743 |
| RYDEX SERIES FUNDS | 2025-12-31 | Class H | RYMDX | 145 | 23,759.7 | 0.1743 |
| RYDEX SERIES FUNDS | 2025-12-31 | Class C | RYHCX | 397 | 65,052.42 | 0.3634 |
| RYDEX SERIES FUNDS | 2025-12-31 | Class A | RYHEX | 397 | 65,052.42 | 0.3634 |